Meta-Analysisvery high evidence
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria: A Meta-Analysis.
JAMA·January 20, 2026·PMID 41203232
Why it mattersPrior uncertainty existed about SGLT2 inhibitor efficacy in advanced CKD or low albuminuria. This analysis provides robust evidence that kidney protection extends to these groups, supporting broader use in patients with type 2 diabetes, CKD, or heart failure regardless of kidney function or albuminuria level.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled